Lorigerlimab
As of the edition of 20 October 2026, Lorigerlimab is an antibody: in active development; acts on CTLA4 and PDCD1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 9, 2 stopped early
- Disease areas
- Cancer; Digestive system; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 7 | 1 | 4 | 2 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| MacroGenics | Lead sponsor of trials | 2018 to now |